CGRP Therapies Reduced Migraine Days
Systematic review found high-certainty evidence for several calcitonin gene–related peptide–targeted therapies
By
Andrea Surnit
May 20, 2026
Clinical Scorecard: CGRP Therapies Reduced Migraine Days
At a Glance
Category Detail
Condition Chronic Migraine Key Mechanisms CGRP-targeted therapies Target Population Adults with chronic migraine (≥15 headache days/month, ≥8 with migraine features) Care Setting Outpatient
Key Highlights
CGRP therapies reduced monthly migraine headache days by about 2 days vs placebo. High-certainty evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and atogepant. Fremanezumab and erenumab showed high-certainty evidence for achieving at least a 50% reduction in migraine days. Galcanezumab likely reduced dropout rates compared to placebo. Erenumab and atogepant likely increased risks of constipation and nausea. Guideline-Based Recommendations
Diagnosis
Chronic migraine defined as headache on ≥15 days/month with ≥8 days featuring migraine characteristics. Management
Consider CGRP-targeted therapies for chronic migraine prophylaxis. Monitoring & Follow-up
Monitor for adverse events, particularly gastrointestinal symptoms. Risks
Increased risk of constipation and nausea with erenumab and atogepant. Patient & Prescribing Data
Adults with chronic migraine
CGRP-targeted therapies are probably effective; consider individual response and tolerability.
Clinical Best Practices
Encourage participation in larger independent trials for better comparative data. Assess long-term safety and efficacy of CGRP therapies. Related Resources & Content
